-10.90 (-0.92%) Dr. Reddy’s Laboratories has informed that it enclosed a press release titled ‘Dr. Reddy’s successfully completes Phase I study (IV route) of DRL_TC, a proposed biosimilar of tocilizumabp’.
The above information is a part of company’s filings submitted to BSE.